Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,449 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.
Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I, Takeuchi M, Yagasaki F, Kawai Y, Miyawaki S, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R; Japan Adult Leukemia Study Group. Towatari M, et al. Among authors: takeuchi m, takeuchi j. Blood. 2004 Dec 1;104(12):3507-12. doi: 10.1182/blood-2004-04-1389. Epub 2004 Aug 17. Blood. 2004. PMID: 15315963 Free article. Clinical Trial.
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Kobayashi T, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Emi N, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R; Japan Adult Leukemia Study Group. Yanada M, et al. Among authors: takeuchi m, takeuchi j. J Clin Oncol. 2006 Jan 20;24(3):460-6. doi: 10.1200/JCO.2005.03.2177. Epub 2005 Dec 12. J Clin Oncol. 2006. PMID: 16344315 Clinical Trial.
Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy.
Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Nishii K, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Narimatsu H, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R; Japan Adult Leukemia Study Group. Yanada M, et al. Among authors: takeuchi m, takeuchi j. Haematologica. 2008 Feb;93(2):287-90. doi: 10.3324/haematol.11891. Epub 2008 Jan 26. Haematologica. 2008. PMID: 18223280 Free article. Clinical Trial.
Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
Yanada M, Sugiura I, Takeuchi J, Akiyama H, Maruta A, Ueda Y, Usui N, Yagasaki F, Yujiri T, Takeuchi M, Nishii K, Kimura Y, Miyawaki S, Narimatsu H, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R; Japan Adult Leukemia Study Group. Yanada M, et al. Among authors: takeuchi m, takeuchi j. Br J Haematol. 2008 Nov;143(4):503-10. doi: 10.1111/j.1365-2141.2008.07377.x. Br J Haematol. 2008. PMID: 18986386 Free article. Clinical Trial.
The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis.
Nishimori H, Matsuo K, Maeda Y, Nawa Y, Sunami K, Togitani K, Takimoto H, Hiramatsu Y, Kiguchi T, Yano T, Yamane H, Tabayashi T, Takeuchi M, Makita M, Sezaki N, Yamasuji Y, Sugiyama H, Tabuchi T, Kataoka I, Fujii N, Ishimaru F, Shinagawa K, Ikeda K, Hara M, Yoshino T, Tanimoto M; West-Japan Hematology and Oncology Group (West-JHOG). Nishimori H, et al. Among authors: takeuchi m. Int J Hematol. 2009 Apr;89(3):326-331. doi: 10.1007/s12185-009-0259-8. Epub 2009 Mar 27. Int J Hematol. 2009. PMID: 19326060
[Therapeutic choice for the chronic myeloid leukemia patients in chronic phase showing late suboptimal response to imatinib].
Matsumura I, Nannya Y, Nagai T, Tanimoto K, Fujikawa K, Kasai M, Inaguma Y, Takeuchi M, Niimi H, Kashiwagi H, Imamura Y, Yagi T, Sakamoto E, Okabe M, Aoki G, Katayama T, Okada M, Adachi Y, Saburi Y, Kizaki M. Matsumura I, et al. Among authors: takeuchi m. Rinsho Ketsueki. 2010 Dec;51(12):1762-8. Rinsho Ketsueki. 2010. PMID: 21258186 Japanese.
Phase II study of intensified rituximab induction and maintenance for low grade B cell lymphoma.
Nagai H, Shimomura T, Takeuchi M, Hanada S, Komeno T, Sunami K, Hidaka M, Yano T, Kitano K, Yoshida I, Inoue N, Saito A, Horibe K, Motitani S, Ichihara S, Watanabe T, Sawamura M. Nagai H, et al. Among authors: takeuchi m. Leuk Lymphoma. 2017 Dec;58(12):2845-2851. doi: 10.1080/10428194.2017.1319054. Epub 2017 May 16. Leuk Lymphoma. 2017. PMID: 28509595 Clinical Trial.
4,449 results